Impact of Unrecognized Myocardial Scar Detected by Cardiac Magnetic Resonance Imaging on Event-Free Survival in Patients Presenting With Signs or Symptoms of Coronary Artery Disease

DOI Web Site 被引用文献17件
  • Raymond Y. Kwong
    From the Cardiovascular Division (R.Y.K., A.K.C., C.W.C., S.T.), Department of Medicine, Brigham and Women’s Hospital, Boston, Mass; the Cardiology Unit (K.A.B.), University of Vermont College of Medicine, Burlington, Vt; General Electric Healthcare (H.G.R.), Boston, Mass; and the Division of General Medicine and Primary Care (R.B.D.), Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass.
  • Anna K. Chan
    From the Cardiovascular Division (R.Y.K., A.K.C., C.W.C., S.T.), Department of Medicine, Brigham and Women’s Hospital, Boston, Mass; the Cardiology Unit (K.A.B.), University of Vermont College of Medicine, Burlington, Vt; General Electric Healthcare (H.G.R.), Boston, Mass; and the Division of General Medicine and Primary Care (R.B.D.), Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass.
  • Kenneth A. Brown
    From the Cardiovascular Division (R.Y.K., A.K.C., C.W.C., S.T.), Department of Medicine, Brigham and Women’s Hospital, Boston, Mass; the Cardiology Unit (K.A.B.), University of Vermont College of Medicine, Burlington, Vt; General Electric Healthcare (H.G.R.), Boston, Mass; and the Division of General Medicine and Primary Care (R.B.D.), Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass.
  • Carmen W. Chan
    From the Cardiovascular Division (R.Y.K., A.K.C., C.W.C., S.T.), Department of Medicine, Brigham and Women’s Hospital, Boston, Mass; the Cardiology Unit (K.A.B.), University of Vermont College of Medicine, Burlington, Vt; General Electric Healthcare (H.G.R.), Boston, Mass; and the Division of General Medicine and Primary Care (R.B.D.), Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass.
  • H. Glenn Reynolds
    From the Cardiovascular Division (R.Y.K., A.K.C., C.W.C., S.T.), Department of Medicine, Brigham and Women’s Hospital, Boston, Mass; the Cardiology Unit (K.A.B.), University of Vermont College of Medicine, Burlington, Vt; General Electric Healthcare (H.G.R.), Boston, Mass; and the Division of General Medicine and Primary Care (R.B.D.), Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass.
  • Sui Tsang
    From the Cardiovascular Division (R.Y.K., A.K.C., C.W.C., S.T.), Department of Medicine, Brigham and Women’s Hospital, Boston, Mass; the Cardiology Unit (K.A.B.), University of Vermont College of Medicine, Burlington, Vt; General Electric Healthcare (H.G.R.), Boston, Mass; and the Division of General Medicine and Primary Care (R.B.D.), Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass.
  • Roger B. Davis
    From the Cardiovascular Division (R.Y.K., A.K.C., C.W.C., S.T.), Department of Medicine, Brigham and Women’s Hospital, Boston, Mass; the Cardiology Unit (K.A.B.), University of Vermont College of Medicine, Burlington, Vt; General Electric Healthcare (H.G.R.), Boston, Mass; and the Division of General Medicine and Primary Care (R.B.D.), Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass.

抄録

<jats:p> <jats:bold> <jats:italic>Background—</jats:italic> </jats:bold> Contrast-enhanced cardiac magnetic resonance imaging (CMR) can determine the extent of myocardial scar from infarction (MI). However, the prognostic significance of unrecognized myocardial scar by CMR in patients without a history of MI is unknown. </jats:p> <jats:p> <jats:bold> <jats:italic>Methods and Results—</jats:italic> </jats:bold> One hundred ninety-five patients without a known prior MI underwent CMR for assessment of left ventricular (LV) function and late gadolinium enhancement (LGE). We assessed the prognostic value of LGE and other CMR variables beyond the strongest clinical predictors and built the best overall models for major adverse cardiac events (MACE) and cardiac mortality. During a median follow-up of 16 months, 31 patients (18%) experienced MACE, including 17 deaths. LGE demonstrated the strongest unadjusted associations with MACE and cardiac mortality (hazard ratios of 8.29 and 10.9, respectively; both <jats:italic>P</jats:italic> <0.0001). Patients in the lowest tertile of LGE-involved myocardium (mean LV mass, 1.4%) experienced a >7-fold increased risk for MACE. By multivariable analyses, LGE was independently associated with MACE beyond the clinical model ( <jats:italic>P</jats:italic> <0.0001) or the clinical model combined with angiographically significant coronary stenosis ( <jats:italic>P</jats:italic> =0.0007), LV ejection fraction ( <jats:italic>P</jats:italic> =0.001), LV end-systolic volume index ( <jats:italic>P</jats:italic> =0.0006), or segmental WMA ( <jats:italic>P</jats:italic> =0.002). LGE remained the strongest predictor selected in the best overall models for MACE and cardiac mortality. </jats:p> <jats:p> <jats:bold> <jats:italic>Conclusions—</jats:italic> </jats:bold> Among patients with a clinical suspicion of coronary artery disease but without a history of MI, LGE involving a small amount of myocardium carries a high cardiac risk. In addition, LGE provides incremental prognostic value to MACE and cardiac mortality beyond common clinical, angiographic, and functional predictors. </jats:p>

収録刊行物

  • Circulation

    Circulation 113 (23), 2733-2743, 2006-06-13

    Ovid Technologies (Wolters Kluwer Health)

被引用文献 (17)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ